Dr. Reddy’s Laboratories announced the launch of Pramipexole Dihydrochloride Extended-Release Tablets, the generic version of Boehringer Ingelheim’s Mirapex ER.

Mirapex ER is a non-ergot dopamine agonist indicated for idiopathic Parkinson’s disease. It has high relative in vitro specificity and full intrinsic activity at the D2 subfamily of dopamine receptors, binding with higher affinity to D3 than to D2 or D4 receptor subtypes. The precise mechanism of action as a treatment for Parkinson’s disease is unknown, although it is believed to be related to its ability to stimulate dopamine receptors in the striatum.

RELATED: Why Malaria Drugs Could Be the Future for Parkinson’s Disease

Pramipexole Dihydrochloride Extended-Release Tablets are available in 0.375mg, 0.75mg, 1.5mg, 3mg, and 4.5mg strengths in 30-count bottles.

For more information call (866) 733-3952 or visit DrReddys.com.